Back

Acute degron-mediated RUNX1 loss reprograms enhancer activity to epigenetically drive epithelial destabilization and initiate cancer hallmarks

Fritz, A.; Greenyer, H.; Dillac, L.; Chavarkar, P.; Ullah, R.; Malik, M.; Hong, D.; Toor, R.; Pacht, E.; Person, A.; Zotkin, G.; Korzec, S.; Gao, C.; Abuarqoub, A.; Warren, J.; Del Porto, J.; Perelman, J.; Montecino, M.; Lian, J.; Van Wijnen, A.; Heath, J.; Ghule, P.; Frietze, S.; Stengal, K.; Reed, K. S. M.; Misteli, T.; Gordon, J.; Stein, J.; Stein, G.

2026-03-28 cancer biology
10.64898/2026.03.26.711344 bioRxiv
Show abstract

The RUNX1 transcription factor mediates cell-type specific gene expression. RUNX1 suppression and perturbations are recurrently associated with breast tumor initiation and progression. However, the mechanisms governing the dual roles of RUNX1 in sustaining the mammary epithelial phenotype while epigenetically suppressing initiation of cancer-compromised gene expression are poorly understood. To address this, we used the power of degron-mediated acute, selective, and complete RUNX1 ablation in human mammary epithelial cells. RUNX1 mediates promoter and distal enhancer-driven expression of a gene cohort. Dynamic epigenomic responsiveness upon RUNX1 ablation reveals a rapid and selective decrease in chromatin accessibility and H3K27ac at RUNX1-bound enhancers, but not promoters. While differentially initiated and expressed genes contacted by RUNX1-bound enhancers are enriched in pathways involved in epithelial maintenance and stemness, genes with RUNX1-promoter occupancy support DNA damage responsiveness. Modified cell morphology, metabolic control, increased breast cancer stemness, plasticity, anchorage-independent survival, chemoresistance, and perturbed DNA damage reactivity are observed upon RUNX1 ablation. Together, these findings define RUNX1 as an epigenetic tumor suppressor that maintains epithelial cell state by preserving enhancer activity and preventing gene expression associated with hallmarks of cancer.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Developmental Cell
168 papers in training set
Top 1%
12.4%
2
Cell Reports
1338 papers in training set
Top 2%
12.1%
3
Molecular Cell
308 papers in training set
Top 1%
10.2%
4
Nature Communications
4913 papers in training set
Top 19%
9.9%
5
Nature Cell Biology
99 papers in training set
Top 0.3%
8.2%
50% of probability mass above
6
Cancer Research
116 papers in training set
Top 0.4%
4.7%
7
Nature Genetics
240 papers in training set
Top 2%
4.7%
8
Science
429 papers in training set
Top 9%
3.5%
9
Nature
575 papers in training set
Top 7%
3.5%
10
Cancer Discovery
61 papers in training set
Top 0.7%
3.0%
11
eLife
5422 papers in training set
Top 33%
2.5%
12
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 30%
1.8%
13
Genes & Development
90 papers in training set
Top 0.5%
1.7%
14
Nature Structural & Molecular Biology
218 papers in training set
Top 3%
1.7%
15
Nature Cancer
35 papers in training set
Top 0.9%
1.3%
16
Science Advances
1098 papers in training set
Top 22%
1.3%
17
The EMBO Journal
267 papers in training set
Top 3%
1.2%
18
Cell Genomics
162 papers in training set
Top 5%
0.9%
19
Cell
370 papers in training set
Top 15%
0.9%
20
Cell Systems
167 papers in training set
Top 11%
0.8%
21
Immunity
58 papers in training set
Top 4%
0.7%
22
Oncogene
76 papers in training set
Top 2%
0.7%
23
Journal of Experimental Medicine
106 papers in training set
Top 4%
0.7%
24
Genome Medicine
154 papers in training set
Top 9%
0.7%
25
Nucleic Acids Research
1128 papers in training set
Top 20%
0.6%